Pharma Investors in Europe

GHO Capital, short for Global Healthcare Opportunities, is a leading European specialist investment firm focused exclusively on the global healthcare sector. Founded to address the growing demand for innovation, scalability, and improved patient outcomes, GHO partners with management teams to build world-class businesses that meet critical healthcare needs globally.With a thematic investment strategy, GHO Capital targets subsectors that benefit from long-term tailwinds such as healthcare outsourcing, digital health, medical technology, and pharmaceuticals. The firm typically invests in growth-stage companies across Europe and North America, providing not only capital but also strategic guidance, industry insight, and operational support to accelerate scale and impact.GHO Capital manages several billion dollars in assets and operates with a strong commitment to sustainability and governance. The firm’s approach integrates environmental, social, and governance (ESG) principles throughout the investment lifecycle, aiming to create long-term value for investors, patients, and healthcare systems alike.

Iron Wolf Capital is a venture capital firm based in Vilnius, Lithuania, with additional offices in London and Tallinn. Founded in 2018, the firm focuses on early-stage investments in deep tech and AI startups originating from the Baltics and the Baltic diaspora. Their investment approach emphasizes supporting innovative teams with global aspirations, providing not only capital but also strategic guidance and access to international networks. With a typical initial investment ranging from €0.5 million to €2 million, Iron Wolf Capital prefers to lead or co-lead funding rounds. The firm has a strong track record, having invested in over 20 startups across sectors such as photonics, robotics, AI, education, pharma, and agritech. Their commitment to fostering innovation is further demonstrated by their active involvement in the Baltic startup ecosystem, including hosting events and publishing industry reports. Iron Wolf Capital places a strong emphasis on Environmental, Social, and Governance (ESG) considerations in their investment decisions. They are licensed by the Bank of Lithuania and are members of several industry associations, including the Lithuanian Private Equity and Venture Capital Association. Their cornerstone investor is Invega, a Lithuanian state-established financial institution.

Namarel Ventures S.L., founded on June 7, 2021, is a Barcelona‑based early‑stage venture capital firm and holding company focused on healthcare innovation. With a small, agile team, it invests in medical devices, diagnostics and digital health startups. The firm targets pre‑seed and seed stage opportunities, often co‑investing with business angels or other VC firms. It supports entrepreneurs with sector expertise, mentoring and access to networks, and provides follow‑on capital selectively to high performance companies. Namarel's mission is to drive disruptive healthcare innovation with global reach, investing primarily in Spain but open to supporting solutions with the potential to improve patient outcomes and reduce costs worldwide.

Nina Capital, founded in 2019 and headquartered in Barcelona, is a specialized venture capital firm investing in early‑stage health technology companies with global ambitions. The firm focuses on need‑driven founders building innovations in diagnostics, medical devices, clinician training, healthcare infrastructure, and data‑driven clinical pathways. Initial investments range from €200 000 to €1.5 million, with capital reserved for follow‑on rounds. In early 2025 Nina Capital closed its €50 million Fund III, bringing assets under management to over €100 million. With a portfolio spanning more than 50 companies across Europe, North America, Israel, Canada and Australia, ​the team applies strategic insight, operational hands‑on support, and a Stanford Biodesign‑inspired methodology to help founders scale.

Omega Funds is a global investment firm focused on identifying and supporting transformational companies in the life sciences sector. With a mission to improve human health, Omega Funds primarily invests in biopharmaceuticals, medical technologies, diagnostics, and digital health. The firm backs science-driven innovation and partners with entrepreneurs developing breakthrough products across the U.S. and Europe.Founded in 2004, Omega Funds manages approximately $2 billion in assets under management. Its investment strategy spans early to late-stage private companies, as well as select public market opportunities. Omega’s portfolio includes a wide range of pioneering biotech firms tackling high-impact areas such as oncology, rare diseases, neurodegeneration, and gene therapies.Headquartered in Boston, Massachusetts, with an additional presence in London, Omega Funds has built a reputation for deep sector knowledge, long-term support, and close collaboration with scientific founders. The firm often takes a hands-on approach, contributing to company strategy, governance, and clinical development to help build lasting and valuable businesses.As a specialist life sciences investor, Omega Funds continues to pursue opportunities that align with its vision of delivering meaningful therapeutic innovation. Its global perspective and scientific focus make it a key player in the advancement of next-generation healthcare solutions.